share_log

Credit Suisse Reiterates Outperform on Mineralys Therapeutics, Maintains $38 Price Target

Benzinga ·  May 16, 2023 07:20

Credit Suisse analyst Richard Law reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Outperform and maintains $38 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment